Drug intelligence / Profile preview

EcN-Apt@HG

Development stage: Preclinical
Lead developer: University of Macau
Modality: RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, Hydrogel Systems → Drug Delivery Systems, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**EcN-Apt@HG** is a research-stage, orally administered inflammation-targeted probiotic delivery system for ulcerative colitis. It comprises *Escherichia coli* Nissle 1917 modified on its surface with an interleukin-6-binding aptamer and encapsulated in a dynamic hydrogel formed from aldehyde-functionalized chondroitin sulfate and amine-terminated poly(amidoamine). The IL-6 aptamer promotes retention at inflamed intestinal sites, while hydrogel encapsulation protects bacterial viability during gastrointestinal transit and supports colonic colonization. In dextran sulfate sodium-induced colitis mouse models, the system restored mucosal barrier function, reduced hyperactive immune responses, remodeled gut dysbiosis, and improved depression-like behavior and cognitive impairment through gut-brain-axis-associated effects. It has not been reported as a clinical-stage or marketed product. ([sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0142961225000821))

Other names: EcN-Apt@HG

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on EcN-Apt@HG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EcN-Apt@HG.

Explore the full profile